Osborne Clarke advised ImmunXperts on its sale to Nexelis

Written on 9 March 2020

International legal practice Osborne Clarke advised ImmunXperts, a speciality Immunogenicity and immuno-oncology testing laboratory, on their acquisition by Nexelis, a portfolio company of Ampersand Capital Partners, and a leading provider of assay development and advanced laboratory testing.

 The parties signed the definitive agreements for this acquisition on March 4, 2020, which is still subject to the realization of various precedent conditions. The closing of the transaction is expected by the end of March.

The Osborne Clarke team was led by Partner Hadrien Chef and included Tonya Aelbrecht, Olivier Lambillon, Margo Cornette, Benjamin Docquir and Thierry Viérin. Osborne Clarke had previously advised ImmunXperts on fundraising and governance matters.